Our Mission...
is to improve the quality of health service delivery and reduce the burden of disease and disability in the United States and elsewhere by carrying out broadly based research and education activities involving the translation of innovative medical research into practice

PUBLICATIONS

2012
2011
2010
2009
2008
2007
2006
2005
2004

 

2010

 

Botkin JR, Teutsch SM, Kaye CI, Hayes M, Haddow JE, Bradley LA, Szegda K, Dotson WD; on behalf of the EGAPP Working Group. Outcomes of interest in evidence-based evaluations of genetic tests. Genet Med, 12:228-235, 2010.

Craig WY, Roberson M, Palomaki GE, Shackleton CHL, Marcos J, Haddow JE: Prevalence of steroid sulfatase deficiency in California according to race and ethnicity. Prenat Diagn, 30:893-898, 2010.

Gudgeon JM, Palomaki GE, Williams MS: Rapid evidence-based reviews of genetic tests. In: Human Genome Epidemiology, 2nd Edition. Khoury MJ, Bedrosian SR, Gwinn ML, Higgins JPT, Ioannidis JPA, Little J (eds). Oxford University Press, 482-496, 201

Haddow JE, Cleary-Goldman J, McClain MR, Palomaki GE, Neveux LM, Lambert-Messerlian G, Canick JA, Malone FD, Porter TF, Nyberg DA, Bernstein PS, D'Alton ME: Thyroperoxidase and thyroglobulin antibodies in early pregnancy and preterm delivery. Obstet Gynecol, 116:58-62, 2010.

Haddow JE : Hypothyroidism: detecting and treating early symptoms as the body’s energy rheostat is slowly turned down. J Med Screen, 17:163, 2010.

Lambert-Messerlian G, Palomaki GE, Canick JA: Examination of the pregnancy-associated plasma protein-A on the Beckman Coulter Access platform: suitability for use in first trimester Down's syndrome screening. J Med Screen, 17:109-113, 2010.

MacRae AR, Chodirker BN, Davies GA, Palomaki GE, Knight GJ, Minett J, Kavsak PA, Toi A, Chitayat D, Van Caeseele PG: Second and first trimester estimation of risk for Down syndrome: implementation and performance in the SAFER study. Prenat Diagn, 30:459-466, 2010.

McClain MR, Palomaki GE, Piper M, Haddow JE: A Rapid-ACCE Review of CYP2C9 and VKORC1 allele testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. In: Human Genome Epidemiology, 2nd Edition. Khoury MJ, Bedrosian SR, Gwinn ML, Higgins JPT, Ioannidis JPA, Little J (eds). Oxford University Press, pp. 620-638, 2010.

Mvundura M, Grosse SD, Hampel Heather, Palomaki GE: The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med, 12:93-104, 2010.

Palomaki GE, Knight GJ, Lambert-Messerlian G, Canick JR, Haddow JE: Four years' experience with an inter-labroatory comparison program involving first trimester markers of Down syndrome. Arch Pathol Lab Med, 134:1685-1691, 2010.

Palomaki GE, Melillo S, Bradley LA: Association between 9p21 genomic markers and heart disease. JAMA, 303:648-656, 2010.

Palomaki GE, Melillo S, Neveux L, Douglas MP, Dotson WD, Janssens ACJW, Balkite EA, Bradley LA: Use of genomic profiling to assess risk for cardiovascular diseasen and identify individualized prevention strategies -- a targeted evidenced-based review. Genet Med, 12:772-784, 2010.

Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO: The evaluation of genomic applications in practice and prevention (EGAPP) initiative: Methods of the EGAPP working group. In: Human Genome Epidemiology, 2nd Edition. Khoury MJ, Bedrosian SR, Gwinn ML, Higgins JPT, Ioannidis JPA, Little J (eds). Oxford University Press, pp. 458-481, 2010.